Enliven Therapeutics Secures $460 Million in Upsized Public Offering
Burlingame-based Enliven Therapeutics has closed an upsized public offering, raising approximately $460 million in gross proceeds. The biopharmaceutical company finalized the sale of over 10.5 million shares of common stock and pre-funded warrants, bolstered by the full exercise of an underwriters' option to acquire additional equity.
The offering saw shares priced at $37.50, with pre-funded warrants sold at $37.499 to specific investors. By exercising their option for 1.6 million additional shares, underwriters signaled strong demand for the clinical-stage firm, which specializes in small molecule therapeutics.
Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays served as joint book-running managers for the transaction. Mizuho joined as a book-running manager, with LifeSci Capital, Baird, and Jones also participating in the management of the offering. The capital raise was conducted under a registration statement previously filed with the U.S. Securities and Exchange Commission in August 2025.
Comments (0)
No comments yet. Be the first!